Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.

@article{Gaspari2018DapagliflozinAH,
  title={Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.},
  author={Tracey Gaspari and Iressa Spizzo and Hongbin Liu and Yunshan Hu and Richard W. Simpson and Robert E. Widdop and Anthony E. Dear},
  journal={Diabetes & vascular disease research},
  year={2018},
  volume={15 1},
  pages={
          64-73
        }
}
BACKGROUND Sodium glucose transporter type 2 inhibitors may reduce cardiovascular events in type 2 diabetes. Our study aimed to determine the effect of the sodium glucose transporter type 2 inhibitor dapagliflozin on endothelial cell activation, vasoreactivity and atherogenesis using in vitro and in vivo models and identify associated molecular mechanisms. METHODS In vitro studies utilised human vascular endothelial cells stimulated with tumour necrosis factor α or hyperglycaemic conditions… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Similar Papers

Loading similar papers…